Woodline Partners LP Boosts Stake in Enovis Co. (NYSE:ENOV)

Woodline Partners LP boosted its stake in shares of Enovis Co. (NYSE:ENOV - Free Report) by 64.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 195,408 shares of the company's stock after acquiring an additional 76,408 shares during the quarter. Woodline Partners LP owned about 0.34% of Enovis worth $8,575,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Enovis by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock worth $240,731,000 after acquiring an additional 75,348 shares during the last quarter. DAVENPORT & Co LLC increased its stake in Enovis by 6.0% during the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock worth $121,181,000 after acquiring an additional 157,216 shares during the last quarter. Royce & Associates LP increased its stake in Enovis by 2.8% during the fourth quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock worth $108,409,000 after acquiring an additional 66,891 shares during the last quarter. River Road Asset Management LLC grew its stake in shares of Enovis by 3.8% during the fourth quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock valued at $54,339,000 after buying an additional 45,762 shares during the last quarter. Finally, Boston Partners grew its stake in shares of Enovis by 27.1% during the fourth quarter. Boston Partners now owns 1,048,532 shares of the company's stock valued at $46,034,000 after buying an additional 223,816 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Trading Down 1.5%

Shares of NYSE ENOV traded down $0.50 during trading hours on Wednesday, reaching $32.94. The stock had a trading volume of 116,393 shares, compared to its average volume of 785,894. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -15.06 and a beta of 1.79. The business's fifty day moving average price is $34.45 and its two-hundred day moving average price is $40.86. Enovis Co. has a 52-week low of $29.32 and a 52-week high of $51.00.

Enovis (NYSE:ENOV - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. The firm had revenue of $558.83 million during the quarter, compared to analyst estimates of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis's quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.50 earnings per share. Analysts expect that Enovis Co. will post 2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ENOV shares. Needham & Company LLC cut their target price on Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group cut their target price on Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, JMP Securities cut their target price on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $58.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.